Signaling through RAS-RAF-MEK-ERK: from basics to bedside
Related Experiment Video
Updated: Jul 16, 2026

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
Published on: July 17, 2019
Armin Zebisch1, Armin P Czernilofsky, György Keri
1Division of Hematology, Medical University of Graz, Graz, Austria.
Abstract:
Aberrant signaling caused by mutations in the RAS-RAF-MEK-ERK pathway and its upstream activators critically contributes to human tumor development. Strategies, which aim at inhibiting hyperactive signaling molecules, appear conceptually straight forward, but their translation into clinical practice has been hampered by many setbacks. Understanding structure, function and regulation of this intracellular pathway as well as its crosstalk with other signaling activities in the cell will be essential to ensure reasonable usage of new therapeutic possibilities. This review provides an understanding of this signaling cascade as revealed by genetic and biochemical approaches and discusses the existing or arising possibilities to interfere with unphysiological activation in cancer. Signaling aberrations and signal transduction therapies will be discussed exemplary for two types of hematological neoplasia, acute myeloid leukemia (AML) and the myelodysplastic syndromes (MDS). In the future understanding the role of tumor stem cells, both as a source of tumor recurrence and tumor heterogeneity, the signals controlling their fate as well as epigenetic changes in cancer will be the next critical steps to further advance the applicability of these novel therapeutic strategies.
Insights
Aberrant RAS-RAF-MEK-ERK pathway signaling drives cancer. This review explores therapeutic strategies targeting this pathway, focusing on hematological cancers like acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Area of Science:
- Oncology
- Molecular Biology
- Signal Transduction
Background:
- Mutations in the RAS-RAF-MEK-ERK pathway are key drivers of human tumor development.
- Targeting hyperactive signaling molecules presents therapeutic potential but faces clinical translation challenges.
- Understanding pathway crosstalk and regulation is crucial for effective therapeutic strategies.
Purpose of the Study:
- To review the structure, function, and regulation of the RAS-RAF-MEK-ERK signaling cascade.
- To discuss current and emerging therapeutic strategies for interfering with aberrant signaling in cancer.
- To examine signal transduction therapies in the context of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Main Methods:
- Genetic and biochemical approaches to elucidate signaling pathways.
- Review of existing literature on signal transduction and cancer therapy.
- Exemplary discussion of therapeutic strategies in specific hematological malignancies.
Main Results:
- Aberrant signaling in the RAS-RAF-MEK-ERK pathway is a critical factor in tumorigenesis.
- Various strategies exist to inhibit hyperactive signaling molecules, though clinical success is variable.
- Understanding pathway dynamics is essential for optimizing therapeutic interventions.
Conclusions:
- Further research into tumor stem cells, their signaling, and epigenetic changes is vital for advancing novel therapeutic strategies.
- Targeting the RAS-RAF-MEK-ERK pathway offers promise for cancer treatment, particularly in AML and MDS.
- Comprehensive understanding of intracellular signaling is key to overcoming therapeutic setbacks.
Related Concept Videos
MAPK Signaling Cascades
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
The Ras Gene
Ras is a superfamily...
Amplifying Signals via Enzymatic Cascade
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...

